Sourc Site (EDGAR):1999 10-K


Employees

     As of December 31, 1999, KeraVision had 172 full-time employees consisting of 58 in
manufacturing, 42 in research and development, 49 in sales and marketing, and 23 in general and
administration. KeraVision also has contracts with outside consultants. KeraVision considers
relations with its employees to be good. None of KeraVision's employees are covered by a
collective bargaining agreement.


Properties

     KeraVision's primary manufacturing, R&D and administrative facilities occupy a total of
approximately 53,000 square feet of space in two locations in Fremont, California. The
facilities are subject to leases which expire in 2004. The current monthly rent is approximately
$61,500. The Company's European sales facilities occupy approximately 3,300 square feet of space
in Chatenay-Malabry, France. The facility is subject to a lease which expires in 2005. The
current monthly rent is approximately $4,000. The Company believes that this space is adequate
for its immediate needs, and that it will be able to renew its lease or obtain additional space
as necessary.

-----------------------------------------------
Source Site (EDGAR): 424B1


Excerpt From:
KERAVISION INC /CA/
Form: 424B1   Filing Date: 8/13/99

<document> <text> Employees As of June 30, 1999, KeraVision had 140 full-time employees consisting of 51 in manufacturing, 38 in research and development, 36 in sales and marketing, and 15 in general and administration. KeraVision also has contracts with outside consultants. KeraVision considers relations with its employees to be good. None of KeraVision's employees is covered by a collective bargaining agreement. KeraVision and its business strategy depends in large part on the ability of KeraVision to attract and retain key management, technical, manufacturing, sales and marketing and other operating personnel. KeraVision will need to develop expertise and add skilled personnel or retain consultants in such areas as research and development, clinical testing, government approvals, sales, marketing and manufacturing in the future. The loss of the services of one or more members of the research or management group or the inability to hire additional personnel and develop expertise as needed could have a material adverse effect on KeraVision. KeraVision has an employment agreement with only one of its employees. Properties KeraVision's primary facilities occupy a total of approximately 40,000 square feet of space in two locations in Fremont, California. The facilities are subject to leases which expire in December 1999 for the 13,000 square feet facility, and July 2004 for the 27,000 square feet facility. The larger facilities house the manufacturing, R&D and administrative departments. The smaller facility houses the sales and marketing, regulatory and clinical departments. The current monthly rent is approximately $41,000. KeraVision's European sales facilities occupy approximately 3,300 square feet of space in Chatenay-Malabry, France. The facility is subject to a lease which expires in July 2001. The current monthly rent is approximately $4,500. KeraVision believes that this space is adequate for its immediate needs, and that it will be able to renew its lease or obtain additional space as necessary. MANAGEMENT Directors and Officers of KeraVision The following table sets forth certain information concerning our directors and executive officers: <TABLE> <CAPTION> Name Age Position <S> <C> <C> Thomas M. Loarie/2/ ...... 53 Chairman of the Board, Chief Executive Officer and President Darlene E. Crockett- Vice President, Regulatory Affairs and Clinical Billig................... 46 Research Mark D. Fischer-Colbrie... 43 Vice President, Finance and Administration, and Chief Financial Officer David Heniges............. 55 Vice President, Europe Richard Meader............ 53 Vice President, Quality Assurance Edward R. Newill.......... 46 Vice President, North American Marketing and Sales Thomas A. Silvestrini..... 47 Vice President, Research and Development Michael A. Taylor......... 49 Vice President, Corporate Relations Robert P. Wood............ 40 Vice President, Manufacturing Charles Crocker/1/,/5/ ... 60 Director Lawrence A. Lehmkuhl/1/,/5/ ......... 62 Director Kshitij Mohan/3/ ......... 54 Director Arthur M. Pappas/3/,/4/ .. 51 Director Peter L. Wilson/3/,/4/ ... 54 Director </TABLE> --------------------- /1/Term on board expires in 2000. /2/Term on board expires in 2001. /3/Term on board expires in 2002. /4/Member of Audit Committee. /5/Member of Compensation Committee. Thomas M. Loarie has served as President, Chief Executive Officer and Chairman of the board of directors of KeraVision since September 1987. From 1985 until joining KeraVision, Mr. Loarie served as President of ABA BioManagement, a management service firm specializing in medical technology start-ups, and from 1984 to 1985 he served as President of Novacor Medical Corporation, a manufacturer of cardiovascular implants. Prior to 1984, Mr. Loarie held management positions in four divisions of American Hospital Supply Corporation, now Baxter International, a manufacturer of healthcare products, serving most recently as President of the American Heyer-Schulte Division, where he was responsible for bringing several new implantable devices to the markets of neurosurgery, oncology, urology, plastic surgery and wound management as well as rebuilding American Heyer-Schulte's international business. Mr. Loarie holds a B.S. degree in engineering from the University of Notre Dame and has completed graduate work in business administration at the Universities of Chicago and Minnesota. Mr. Loarie also serves as a director of the Health Industry Manufacturers Association and of the California Healthcare Institute. Darlene E. Crockett-Billig has served as Vice President, Regulatory Affairs and Clinical Research of KeraVision since February 1988. From 1986 to 1988, she served as Regulatory Affairs Manager for CooperVision Ophthalmic Products, an ophthalmic device manufacturer, where she was responsible for all FDA submissions, product approval strategies and regulatory compliance. Prior to that time, Ms. Crockett-Billig spent ten years in management and laboratory supervision positions with Miles Laboratories and 36 <PAGE> Medtronic, Inc., two healthcare products manufacturers. Ms. Crockett-Billig received her B.A. in Biology from Augustana College and her M.B.A. from the College of St. Thomas, Minnesota. Mark D. Fischer-Colbrie has served as Vice President, Finance and Administration and Chief Financial Officer of KeraVision since March 1992. From 1983 to 1992, Mr. Fischer-Colbrie held several senior financial positions, most recently as Vice President, Controller, at Maxtor Corporation, a manufacturer of computer disk drives. Prior to 1983, he worked for four years with a subsidiary of Xerox Corp. in accounting and finance. Mr. Fischer-Colbrie holds a B.A. from Stanford University and an M.B.A. in Finance and Marketing from the University of California at Berkeley. David Heniges has served as Vice President, Europe of KeraVision since July 1998. Mr. Heniges was most recently Vice President Global Marketing for Baxter International's Cardiovascular Surgery Division. Prior to that position, Mr. Heniges was Vice President Worldwide Business Development for IOLAB, a division of Johnson & Johnson. Mr. Heniges worked for Johnson & Johnson for 23 years. Mr. Heniges received his B.S. in Sociology with a minor in Science from Oregon State University. Richard Meader has served as Vice President, Quality Assurance of KeraVision since September 1998. Prior to that time, Mr. Meader was most recently Vice President Regulatory and Quality Affairs for B. Braun/McGaw Inc. During his 23- year tenure with B. Braun/McGaw Inc., Mr. Meader was responsible for introducing the company's Total Quality Management program and instituting efficiencies that reduced quality related costs. Mr. Meader received his B.S. in Chemistry from the University of California Los Angeles. Edward R. Newill has served as Vice President, North American Marketing and Sales of KeraVision since May 1996. Mr. Newill has 20 years of international experience in a broad range of surgical specialties including plastic surgery, which like vision correction surgery is consumer-based and non-reimbursed by insurers. Mr. Newill held management positions with Mentor from 1990 to 1996. Mr. Newill holds a B.S. in General Business from Miami University and a Masters in International Management from American Graduate School of International Management. Thomas A. Silvestrini has served as Vice President, Research and Development of KeraVision since July 1990. Prior to joining KeraVision, Mr. Silvestrini spent 12 years in senior management and project positions, including Manager of Research and Development, Project Leader, and Senior Research Scientist, with the Corporate Research Center of the Hospital Products Group for the Pfizer Corporation, a manufacturer of healthcare products. He has received 11 patents for medical devices and has an additional 12 patents pending. Mr. Silvestrini received his B.S. in Chemical Engineering and his M.S. in Organic Chemistry from the University of Minnesota. Michael A. Taylor has served as Vice President, Corporate Relations since June 1999. He directed KeraVision's communications programs as an outside consultant starting in 1993. Prior to joining KeraVision, Mr. Taylor served as Vice President, Corporate Relations for American Medical International, Inc. He earlier served as a press aide to a member of Congress and as a newspaper reporter. Mr. Taylor holds a B.A. in journalism from Central Oklahoma State University. Robert P. Wood has served as Vice President, Manufacturing of KeraVision since April 1996. From 1994 to 1996, Mr. Wood was Operations Manager of Allergan, Inc.'s Waco, Texas medical device and pharmaceutical facility. From 1987 to 1994 Mr. Wood held management positions with Abbott Laboratories. Mr. Wood holds a B.S. in Mechanical Engineering from Texas A&M University. Charles Crocker has served as a director of KeraVision since January 1987. Mr. Crocker served as Chairman of the Board of BEI Electronics, Inc. from 1974 to September 1997. Since September 1997, Mr. Crocker has served as Chairman, President and CEO of BEI Technologies, Inc., a diversified electronics company specializing in electronic sensors and motion control products, and as Chairman of the Board of BEI Medical Systems Company (formerly BEI Electronics, In.), a medical device company specializing in 37 <PAGE> diagnostic and therapeutic products for the women's healthcare market. He has been President of Crocker Capital, a private venture capital firm, since 1985. Mr. Crocker holds a B.S. degree from Stanford University and a M.B.A. from the University of California at Berkeley. Mr. Crocker also serves as a director of Fiduciary Trust Company International and Pope & Talbot, Inc. Lawrence A. Lehmkuhl has served as a director of KeraVision since August 1992. From 1985 to 1994, Mr. Lehmkuhl was the Chairman, President and Chief Executive Officer of St. Jude Medical, Inc., a medical device manufacturer. Prior to 1985, Mr. Lehmkuhl spent 18 years in management positions with American Hospital Supply Corporation. Mr. Lehmkuhl holds a B.B.A. from the University of Iowa. Mr. Lehmkuhl is also a director of Nutrition Medical, Inc. Kshitij Mohan has served as a director of KeraVision since January 1997. From 1995 to present, Dr. Mohan has served as Corporate Vice President for research and technical services at Baxter International Inc. Dr. Mohan previously served as a director of device evaluation at the Food and Drug Administration's Center for Devices and Radiological Health. Dr. Mohan holds a B.S. in Physics from Patna University, a M.S. in Physics from University of Colorado, and a Ph.D. in Physics from Georgetown University. Dr. Mohan also serves as a director of the Health Industry Manufacturers Association. Arthur M. Pappas has served as a director of KeraVision since January 1997. Mr. Pappas is Chairman and Chief Executive Officer of A.M. Pappas & Associates, LLC, an international consulting, investment and venture company that works with early to mid-stage life science companies, technologies and products. Prior to founding A.M. Pappas & Associates in 1994, he was a director on the main board of Glaxo Holdings plc with executive responsibilities for operations in Asia Pacific, Latin America, and Canada. In this capacity, he was Chairman and Chief Executive Officer of Glaxo Far East (Pte) Ltd. and Glaxo Latin America Inc., as well as Chairman of Glaxo Canada Inc. He has held various senior executive positions with Abbott Laboratories International Ltd., Merrell Dow Pharmaceuticals, and the Dow Chemical Company, in the United States and internationally. Mr. Pappas received a B.S. in biology from Ohio State University and an M.B.A. in finance from Xavier University. Mr. Pappas also serves as a director of Quintiles Transnational Corp., GeneMedicine Inc., Embrex Inc., and AtheroGenics Inc. Peter L. Wilson has served as a director of KeraVision since August 1998. Mr. Wilson is currently President and Chief Executive Officer of Patent Education Systems. He is the former President of Procter & Gamble's Richardson Vicks USA. In 1972, Mr. Wilson joined the marketing department of Richardson Vicks/Merrell Pharmaceuticals, rising to President and General Manager of the Vidal Sassoon Division in 1984 and President and General Manager of the Personal Care Division in 1986. He was appointed president of Richardson Vicks in 1990. Mr. Wilson holds a B.S. in Geology from Princeton University and an M.B.A. from Columbia University. In addition, John Galantic has agreed to accept the position of Chief Operating Officer of KeraVision pending his election to this position by the board of directors. In connection with his employment in July 1999, he was granted an option to purchase 120,000 shares of common stock, which option vests over four years, and a grant of 11,034 shares of restricted stock, which shares are subject to vesting over two years. From January 1997 to July 1999, Mr. Galantic was General Manager of SmithKline Beecham Consumer Healthcare, Belgium. From April 1993 to December 1996, he was Director of Category Management on a global basis for SmithKline Beecham's respiratory and smoking cessation products. Prior to April 1993, Mr. Galantic spent seven years at Proctor & Gamble in a variety of marketing and sales assignments in both the U.S. and Europe. Steven M. Henderson has agreed to accept the position of Vice President, Sales of KeraVision. Previously, Mr. Henderson was U.S. Field Sales Director at Bausch & Lomb's Surgical Division. Prior to that, he was National Sales Director at a division of Chiron Corporation. </text></document></plaintext> </body></html>